Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Drugs in Development
Details:
BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Lead Product(s): BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2020
Lead Product(s) : BP-C2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice
Details : BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Details:
This three-year contract consists of a one-year base period with two one-year optional periods that will allow Meabco to complete IND-enabling studies and advance BP-C2 as a therapy for treating the effects of unintentional radiation exposure.
Lead Product(s): BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: National Institutes of Health
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Funding May 25, 2020
Lead Product(s) : BP-C2
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : $5.9 million
Deal Type : Funding
Details : This three-year contract consists of a one-year base period with two one-year optional periods that will allow Meabco to complete IND-enabling studies and advance BP-C2 as a therapy for treating the effects of unintentional radiation exposure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 25, 2020
Details:
BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BP-C1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cytotoxic Drug
Sponsor: Meddoc | Norwegian University of Life Sciences | Meddoc Research Indonesia | Meddoc Research Taiwan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2020
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 06, 2020
Details:
BP-C2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Lead Product(s): BP-C2
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: Meddoc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2019
Recommended Dose Estimation of BP-C2
Details : BP-C2 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 05, 2019
Details:
BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BP-C1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Meddoc | Norwegian University of Life Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 28, 2018
Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 28, 2018
Details:
BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): BP-C1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Meddoc | Norwegian University of Life Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 13, 2018
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 13, 2018
Details:
BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BP-C1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Meddoc | Norwegian University of Life Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2018
BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer
Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 27, 2018
Details:
BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BP-C1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Meddoc | Norwegian University of Life Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 26, 2016
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 26, 2016
Details:
BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BP-C1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cytotoxic Drug
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2013
BP-C1 in Metastatic Breast Cancer Patients
Details : BP-C1 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 23, 2013
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
